生命科学资讯
生物技术与制药领域的最新动态
赛默飞世尔科技(NYSE:TMO)首席运营官减持22,046股股份 - MarketBeat
Thermo Fisher Scientific (NYSE:TMO) COO Sells 22,046 Shares - MarketBeat
#ASH25: AstraZeneca's dual-targeting CAR-T sees similar responses in Western patients as in China
安捷伦科技股票能否承受更多下行压力?- Trefis分析
Is Agilent Technologies Stock Built to Withstand More Downside? - Trefis
摩根士丹利降级后10x Genomics股价下跌5.5%,牛市逻辑是否生变?
10x Genomics (TXG) Is Down 5.5% After Morgan Stanley Downgrade Has The Bull Case Changed? - simplywall.st
#ASH25:再生元淋巴瘤双特异性药物一扇门关闭,另一扇门开启
#ASH25: As one door closes for Regeneron’s lymphoma bispecific, another reopens
安捷伦科技公司(NYSE:A)近期股价表现是否与其强劲的基本面紧密相连? - 雅虎财经
Is Agilent Technologies, Inc.'s (NYSE:A) Recent Stock Performance Tethered To Its Strong Fundamentals? - Yahoo Finance
Vertex基因编辑疗法在儿童血液疾病治疗中取得早期目标
Vertex CRISPR therapy hits early goal in children with blood disorders
ASH 2025:Casgevy能否用于儿童?镰状细胞病基因疗法的扩展与优化
ASH 2025: Casgevy for kids? Expanding, improving SCD gene therapies
Mirabella金融服务LLP减持赛默飞世尔科技公司股份 $TMO - MarketBeat
Mirabella Financial Services LLP Decreases Stock Holdings in Thermo Fisher Scientific Inc. $TMO - MarketBeat
马歇尔·韦斯律师事务所减持沃特世公司股份 - MarketBeat
Marshall Wace LLP Lowers Stake in Waters Corporation $WAT - MarketBeat
苹果树合伙公司赢得对涉嫌俄罗斯投资者抵制行为的法律诉讼
Apple Tree Partners scores legal win against alleged holdout Russian investor
ACIP投票与FDA更多人事变动;《终点信号》杂志创刊;ARCH与帕克研究所押注下一个癌症疗法;及其他新闻。
ACIP vote, more FDA turnover; Introducing Endpoints Signal; ARCH, Parker Institute building next cancer bet; and more
安捷伦科技股票表现与其他医疗保健股相比如何? - MSN
How is Agilent Technologies' stock performance compared to other healthcare stocks? - MSN
Epoch Investment Partners Inc. 出售53,867股Thermo Fisher Scientific Inc. $TMO股票 - MarketBeat
Epoch Investment Partners Inc. Sells 53,867 Shares of Thermo Fisher Scientific Inc. $TMO - MarketBeat
First Trust Advisors LP出售22,018股Waters Corporation $WAT股份 - MarketBeat
First Trust Advisors LP Sells 22,018 Shares of Waters Corporation $WAT - MarketBeat
安捷伦科技(A)目标股价上调10.53%至170.51美元 - 纳斯达克
Agilent Technologies (A) Price Target Increased by 10.53% to 170.51 - Nasdaq
Illumina (ILMN):股价悄然反弹后估值评估 - 雅虎财经
Illumina (ILMN): Assessing Valuation After a Quiet Share Price Rebound - Yahoo Finance
Illumina (ILMN):股价悄然反弹后估值评估 - 雅虎财经加拿大
Illumina (ILMN): Assessing Valuation After a Quiet Share Price Rebound - Yahoo! Finance Canada
ORIC肺癌药物在特定环境下展现潜力,但针对HER2突变的研究已终止。
ORIC’s lung cancer pill shows promise in some settings but is dropped for HER2 mutations